BTG Gains First U.S. Approval With Methotrexate Antidote Voraxaze

Transatlantic specialty pharma BTG adds to its antidote portfolio with FDA approval of Voraxaze, an enzyme drug that breaks down methotrexate in patients whose kidneys are failing due to high serum levels of the chemotherapeutic. BTG also markets snake-bite therapy CroFab and DigiFab for digitalis overdose and recently licensed a late-stage drug to counter toxicity from 5-FU chemotherapy.